Mount Yale Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Mount Yale Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,770	Closed	-$201K	–	487
2022 Q3	$201K	Sell	3,770 -48	-1%	-$2.67K	0.03%	423
2022 Q2	$223K	Buy	3,818 +179	+5%	+$11.7K	0.03%	418
2022 Q1	$278K	Buy	+3,639	New	+$243K	0.03%	382
2021 Q4	–	Sell	-4,005	Closed	-$224K	–	487
2021 Q3	$224K	Buy	4,005 +17	+0.4%	+$980	0.03%	425
2021 Q2	$242K	Buy	3,988 +583	+17%	+$36.9K	0.03%	371
2021 Q1	$239K	Sell	3,405 -258	-7%	-$18.4K	0.03%	369
2020 Q4	$219K	Buy	+3,663	New	+$214K	0.03%	363

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Mount Yale Investment Advisors's PCRX Position: Q4 2022 in Review

Mount Yale Investment Advisors sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 3,770 shares — an estimated $201K sold.

Mount Yale Investment Advisors first reported a position in PCRX in Q4 2020 and held it in 7 quarters. The position peaked at $278K in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

Mount Yale Investment Advisors reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
Mount Yale Investment Advisors sold 3,770 Pacira BioSciences shares in Q4 2022, an estimated $201K.
Mount Yale Investment Advisors first reported a position in Pacira BioSciences in Q4 2020 and held it in 7 quarters.
Mount Yale Investment Advisors's Pacira BioSciences position peaked at $278K in Q1 2022.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Mount Yale Investment Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.